Apellis Pharmaceuticals, Inc. Common Stock
APLS
$0.00
+0.40%
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing novel therapies by inhibiting the complement system. It is a leader in targeting the C3 protein with its two marketed drugs, SYFOVRE and EMPAVELI, addressing diseases with high unmet medical needs.…
APLS
Apellis Pharmaceuticals, Inc. Common Stock
$0.00
Related headlines
APLS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Apellis Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
9 analysts
Implied Upside
—
vs. current price
Analyst Count
9
covering this stock
Price Range
$0 - $0
Analyst target range
No sufficient analyst coverage available. The provided data includes analyst ratings and actions, but they are from 2024 and do not contain current target prices or a consensus rating as of the analysis date. The recent news of a major acquisition by Biogen has fundamentally altered the investment thesis, making prior analyst targets largely obsolete.
APLS Technical Analysis
The stock has exhibited extreme volatility over the past six months, culminating in a dramatic surge. The price data shows a steady decline from late 2025 through March 2026, falling from around $30 to a low near $17, followed by an explosive 135.4% single-day jump to $40.23 on March 31, 2026. This final surge is the dominant feature of the short-term performance, rendering the 1-month change of +91.94% and the 3-month change of +60.15% as artifacts of this single event rather than a sustained trend. The current price of $40.23 is at the very top of its 52-week range of $16.10 to $40.45, indicating it is trading near its annual high. No RSI data was provided for analysis of overbought or oversold conditions.
Beta
0.29
0.29x market volatility
Max Drawdown
-43.5%
Largest decline past year
52-Week Range
$16-$40
Price range past year
Annual Return
+78.1%
Cumulative gain past year
| Period | APLS Return | S&P 500 |
|---|---|---|
| 1m | +95.1% | -3.7% |
| 3m | +60.8% | -4.1% |
| 6m | +69.7% | -2.1% |
| 1y | +78.1% | +16.1% |
| ytd | +56.2% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APLS Fundamental Analysis
Revenue and profitability have been highly volatile on a quarterly basis. Q3 2025 showed strong performance with $458.6M in revenue and a net income of $215.7M, but this was followed by a significant contraction in Q4 2025 to $199.9M in revenue and a net loss of -$58.95M, representing a year-over-year revenue decline of -5.94%. The company maintains a strong current ratio of 3.14, indicating good short-term liquidity, but carries a debt-to-equity ratio of 1.31, reflecting a leveraged balance sheet. Operationally, the trailing twelve-month return on equity (ROE) is a modest 6.05%, while the latest quarterly free cash flow was negative, though the TTM figure remains positive at $45.3M.
Quarterly Revenue
$199913000.0B
2025-12
Revenue YoY Growth
-0.05%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$45327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APLS Overvalued?
Given the company's inconsistent profitability, with a recent quarterly net loss, the Price-to-Sales (PS) ratio is a more appropriate valuation metric than the P/E ratio. The current PS ratio is 3.15. For peer comparison, the provided valuation data does not include industry average PS ratios, so a relative assessment cannot be made. The forward P/E is deeply negative at -130.57, reflecting expected near-term losses, and the EV/EBITDA of 45.49 is high, indicating the market is pricing in significant future growth.
PE
141.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -30x~3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.5x
Enterprise Value Multiple